In a landmark stride that reinforces its commitment to innovation and accessibility, MeCure Industries PLC has unveiled an impressive portfolio of 19 newly approved pharmaceutical products in 2025, marking one of the most significant expansion phases in the company’s history.
The development signals more than just regulatory milestones — it reflects MeCure’s strategic intent to deepen therapeutic coverage across Nigeria, strengthen its presence in chronic care, and further its mission of “Enriching Lives through Innovation in Pharmaceuticals.”
With non-communicable diseases on the rise in Nigeria, MeCure has significantly expanded its cardiovascular portfolio with the introduction of:
These additions position MeCure as a stronger partner to healthcare providers in managing hypertension, hyperlipidemia, and related cardiac risks — conditions that continue to burden millions of Nigerians. By locally manufacturing these essential medicines, the company strengthens national pharmaceutical independence while ensuring affordability and availability.
In metabolic therapy, the launch of Glibenclamide 5mg Tablet enhances MeCure’s footprint in diabetes management. As the prevalence of type 2 diabetes rises across urban and semi-urban communities, this addition provides physicians with another reliable and cost-effective option from a trusted Nigerian manufacturer.
MeCure’s 2025 portfolio further consolidates its strength in anti-infectives — an area where the company has historically demonstrated manufacturing excellence. New introductions include:
These additions strengthen MeCure’s antibiotic range, supporting healthcare providers in effectively managing bacterial infections. The expansion of the Augmec line builds on the company’s proven capability in producing beta-lactam antibiotics locally — a strategic advantage in ensuring consistent supply within Nigeria.
Recognizing everyday health challenges faced by patients, MeCure has also introduced:
These products address allergies, musculoskeletal pain, inflammatory conditions, and fungal skin infections — broadening MeCure’s therapeutic reach while maintaining its unwavering commitment to quality.
The 2025 approvals align directly with MeCure Industries PLC’s key objectives: enhancing accessibility of its brands across Nigeria, introducing new molecules in the prescription range, strengthening distribution channels, and supporting the national healthcare system with high-quality, locally manufactured medicines.
Backed by cGMP-compliant manufacturing standards and ISO 9001:2015 accreditation, every product launched under the MeCure brand reflects the company’s unwavering dedication to quality, integrity, and accountability.
As economic pressures continue to impact healthcare affordability, MeCure’s strategy of expanding local production becomes even more critical. The 19-product milestone represents not just corporate growth, but a meaningful contribution to improving healthcare access across Nigeria.
With this significant expansion, 2025 stands as a defining year in MeCure’s growth story — reinforcing its position as a leading pharmaceutical manufacturer committed to enriching lives through innovation.